missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CD58/LFA-3 Mouse anti-Human, Clone: 248310, R&D Systems™

Mouse Monoclonal Antibody has been used in 1 publication
Brand: R&D Systems MAB1689-SP
This item is not returnable.
View return policy
Description
CD58/LFA-3 Monoclonal specifically detects CD58/LFA-3 in Human samples. It is validated for Western Blot, Flow Cytometry, CyTOF-ready.Specifications
| CD58/LFA-3 | |
| Monoclonal | |
| LYOPH | |
| Western Blot 1 ug/mL, Flow Cytometry 0.25 ug/10^6 cells, CyTOF-ready | |
| P19256 | |
| CD58 | |
| Mouse myeloma cell line NS0-derived recombinant human CD58/LFA-3 Phe29-Arg215 Accession # P19256 | |
| 25 μg | |
| Primary | |
| Detects human CD58/LFA-3 in direct ELISAs and Western blots. | |
| Human | |
| Purified |
| Western Blot, Flow Cytometry, CyTOF | |
| 248310 | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
| Ag3, CD58, CD58 antigen, CD58 antigen, (lymphocyte function-associated antigen 3), CD58 molecule, FLJ23181, FLJ43722, LFA3, LFA-3, LFA3ag3, lymphocyte function-associated antigen 3, Surface glycoprotein LFA-3 | |
| Mouse | |
| Protein A or G purified from hybridoma culture supernatant | |
| RUO | |
| 965 | |
| Reconstitute at 0.5 mg/mL in sterile PBS. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
| IgG2b |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction